{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-004554","form_type":"8-K","ticker":"GUTS","cik":"0001572616","company_name":"FRACTYL HEALTH, INC.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.039410+00:00","generated_at":"2026-05-28T03:19:16.075868+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fractyl Health: initial REVEAL-1 data show weight maintenance post-GLP-1 discontinuation; REMAIN-1 enrollment strong","bullets":["First REVEAL-1 patient achieved 15% total body weight loss on tirzepatide, then maintained weight 1 month after Revita post-discontinuation.","Prior studies show average 3% weight regain within 4 weeks of GLP-1 discontinuation, highlighting Revita potential.","Over 100 patients enrolled across 8 sites in REMAIN-1 study in less than 4 months; high demand.","REVEAL-1 cohort data presentation delayed to Q1 2025 due to holiday scheduling; mid-point analysis expected Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-004554","json":"https://secwatch.observer/filing/0000950170-25-004554.json","markdown":"https://secwatch.observer/filing/0000950170-25-004554.md","text":"https://secwatch.observer/filing/0000950170-25-004554.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1572616/000095017025004554/0000950170-25-004554-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1572616/000095017025004554/guts-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:19:16.075868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}